March 14, 2017 — Transcatheter aortic valve replacement (TAVR) for aortic stenosis continues to evolve with the adoption ...
Stratasys Ltd. announced last week enrollment is now open for 3DHEART, an investigator-initiated trial. 3DHEART, which stands for 3D Hearts Enabling A Randomized Trial, is a randomized, single-blind clinical trial to study the use of patient-specific 3-D-printed models in pre-operative planning for pediatric heart surgery. Stratasys is providing in-kind support with printing of the models to be used in the trial.
A new research study by the Harvey L. Neiman Health Policy Institute assesses relationships between county-level variation in Medicare beneficiary imaging resource consumption and measures of population economic status. The study, published online in the Journal of the American College of Radiology (JACR), found that in the Medicare population, imaging utilization and costs vary greatly at the county level, and far more than at the state level.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new recommendations on procedures employing gadolinium-based contrast agents, in which the committee recommended suspension of marketing authorization for four agents.
The most prevalent method for obtaining images of clogged coronary vessels is coronary angiography. For some patients, however, the contrast agents used in this process can cause health problems. A team at the Technical University of Munich (TUM) has now demonstrated that the required quantity of these substances can be significantly reduced if monoenergetic X-rays from a miniature particle accelerator are used.
March, 10, 2017 - Medtronic announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Zoll Medical Corp. announced that the company’s Hospital Wearable Defibrillator (HWD) has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) to market and begin U.S. distribution of the device.
Artificial intelligence (AI) has captured the imagination and attention of doctors over the past couple years as several ...
Information technology (IT) is among the least sexy areas to cover in medical technology advances, and is often ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
ITN Editor Dave Fornell takes a tour of some of the most innovative new technology that was displayed on the expo floor ...
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from heart attacks.
To ensure imaging systems are operating safely and at optimum performance with appropriate and preventative maintenance, Toshiba Medical has introduced a customized PM Only Service Agreement to customers. The PM Only Service Agreement allows providers to fulfill and document that they are compliant with the Centers for Medicare & Medicaid (CMS) Directive and The Joint Commission’s (TJC) guidelines of ensuring all imaging equipment meets manufacturers’ specifications.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during high-risk percutaneous coronary intervention (HRPCI) can reduce the risk of acute kidney injury (AKI) even when those patients had pre-existing kidney disease1 and low ejection fraction (EF). The new study builds upon earlier data from PROTECT II, a randomized clinical trial, which found kidney injury rates were numerically lower when more contrast was used during HRPCI, and adds to the growing body of evidence of the benefits of hemodynamic support with Impella during HRPCI, according to Abiomed.
Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-coated balloon (DCB) in patients with below-the-knee (BTK) peripheral arterial disease (PAD). This study will evaluate the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This is an investigational device, which uses Medtronic’s IN.PACT Admiral drug coating technology.